Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 VectorY Enters Collaboration with Wageningen University | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

VectorY Enters Collaboration with Wageningen University

Will work together to develop novel baculovirus-based technologies for the production of safe & affordable AAV gene therapies.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

VectorY Therapeutics, a biotech company focusing on the development of gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, is collaborating with Wageningen University to develop novel baculovirus-based technologies for the production of safe and affordable AAV gene therapies.
 
VectorY, together with its partner Wageningen University, is making a strategic investment in the gene therapies of the future, by developing a production platform capable of successfully manufacturing safe products at a significant lower COGS. The collaboration represents an important step to enable the medical and economic feasibility of gene therapy for diseases that affect larger patient populations.
 
Under the terms of the collaboration, the Bioprocess Engineering and Virology Groups at Wageningen University and VectorY Therapeutics will work together on two projects. One will utilize the molecular toolbox to generate innovative stable baculovirus genome seeds for AAV production at large scale. The second will focus on the design and evaluation of an intensified and scalable baculovirus production process in bioreactors using state of the art bioprocess technologies.
 
“We are very pleased to be collaborating with VectorY to develop proprietary, next generation AAV expression systems and industry-leading bioprocessing capabilities,” said Monique van Oers, professor of Virology, Wageningen University.
 
“We are honored to partner with Wageningen University, a significant pioneer in the Baculovirology and Bioprocessing field. This partnership will further strengthen VectorY’s proprietary AAV production technologies for the development of Next Generation Gene Therapies,” added Alexander Vos, CEO VectorY Therapeutics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters